# World Journal of *Clinical Cases*

World J Clin Cases 2022 October 26; 10(30): 10823-11213





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

Contents

Thrice Monthly Volume 10 Number 30 October 26, 2022

### **REVIEW** New insights into the interplay between intestinal flora and bile acids in inflammatory bowel disease 10823 Zheng L 10840 Role of visfatin in obesity-induced insulin resistance Abdalla MMI **MINIREVIEWS** 10852 Hyperthermic intraperitoneal chemotherapy and colorectal cancer: From physiology to surgery Ammerata G, Filippo R, Laface C, Memeo R, Solaini L, Cavaliere D, Navarra G, Ranieri G, Currò G, Ammendola M 10862 New-onset diabetes secondary to acute pancreatitis: An update Yu XQ, Zhu Q Ketosis-prone diabetes mellitus: A phenotype that hospitalists need to understand 10867 Boike S, Mir M, Rauf I, Jama AB, Sunesara S, Mushtaq H, Khedr A, Nitesh J, Surani S, Khan SA 2022 Monkeypox outbreak: Why is it a public health emergency of international concern? What can we do 10873 to control it? Ren SY, Li J, Gao RD

#### **ORIGINAL ARTICLE**

#### **Retrospective Cohort Study**

10882 Clinical characteristics and prognosis of non-small cell lung cancer patients with liver metastasis: A population-based study

Wang JF, Lu HD, Wang Y, Zhang R, Li X, Wang S

#### **Retrospective Study**

Prevalence and risk factors for Candida esophagitis among human immunodeficiency virus-negative 10896 individuals

Chen YH, Jao TM, Shiue YL, Feng IJ, Hsu PI

Prognostic impact of number of examined lymph nodes on survival of patients with appendiceal 10906 neuroendocrine tumors

Du R, Xiao JW

#### **Observational Study**

10921 Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study

Magrì S, Demurtas M, Onidi MF, Picchio M, Elisei W, Marzo M, Miculan F, Manca R, Dore MP, Quarta Colosso BM, Cicu A, Cugia L, Carta M, Binaghi L, Usai P, Lai M, Chicco F, Fantini MC, Armuzzi A, Mocci G



| -   |
|---|
| S Thrice Monthly Volume 10 Number 30 October 26, 2022   |
| Clinical observation of laparoscopic cholecystectomy combined with endoscopic retrograde cholangiopancreatography or common bile duct lithotripsy   |
| Niu H, Liu F, Tian YB   |
| Prospective Study   |
| Patient reported outcome measures in anterior cruciate ligament rupture and reconstruction: The significance of outcome score prediction            |
| Al-Dadah O, Shepstone L, Donell ST  |
| SYSTEMATIC REVIEWS  |
| Body mass index and outcomes of patients with cardiogenic shock: A systematic review and meta-analysis  |
| Tao WX, Qian GY, Li HD, Su F, Wang Z  |
| META-ANALYSIS   |
| Impact of being underweight on peri-operative and post-operative outcomes of total knee or hip arthroplasty: A meta-analysis                        |
| Ma YP, Shen Q   |
| Branched-chain amino acids supplementation has beneficial effects on the progression of liver cirrhosis: A meta-analysis                            |
| Du JY, Shu L, Zhou YT, Zhang L  |
| CASE REPORT   |
| Wells' syndrome possibly caused by hematologic malignancy, influenza vaccination or ibrutinib: A case report  |
| Šajn M, Luzar B, Zver S   |
| Giant cutaneous squamous cell carcinoma of the popliteal fossa skin: A case report  |
| Wang K, Li Z, Chao SW, Wu XW  |
| Right time to detect urine iodine during papillary thyroid carcinoma diagnosis and treatment: A case report   |
| Zhang SC, Yan CJ, Li YF, Cui T, Shen MP, Zhang JX   |
| Two novel mutations in the <i>VPS33B</i> gene in a Chinese patient with arthrogryposis, renal dysfunction and cholestasis syndrome 1: A case report |
| Yang H, Lin SZ, Guan SH, Wang WQ, Li JY, Yang GD, Zhang SL  |
| Effect of electroacupuncture for Pisa syndrome in Parkinson's disease: A case report  |
| Lu WJ, Fan JQ, Yan MY, Mukaeda K, Zhuang LX, Wang LL  |
| Neonatal Cri du chat syndrome with atypical facial appearance: A case report  |
| Bai MM, Li W, Meng L, Sang YF, Cui YJ, Feng HY, Zong ZT, Zhang HB   |
| Complete colonic duplication presenting as hip fistula in an adult with pelvic malformation: A case report  |
| Cai X, Bi JT, Zheng ZX, Liu YQ  |
|   |



| Conton | World Journal of Clinical Cases  |
|--------|--|
| Conten | Thrice Monthly Volume 10 Number 30 October 26, 2022  |
| 11044  | Autoimmune encephalitis with posterior reversible encephalopathy syndrome: A case report   |
|        | Dai SJ, Yu QJ, Zhu XY, Shang QZ, Qu JB, Ai QL  |
| 11049  | Hypophysitis induced by anti-programmed cell death protein 1 immunotherapy in non-small cell lung cancer: Three case reports                             |
|        | Zheng Y, Zhu CY, Lin J, Chen WS, Wang YJ, Fu HY, Zhao Q  |
| 11059  | Different intraoperative decisions for undiagnosed paraganglioma: Two case reports   |
|        | Kang D, Kim BE, Hong M, Kim J, Jeong S, Lee S  |
| 11066  | Hepatic steatosis with mass effect: A case report  |
|        | Hu N, Su SJ, Li JY, Zhao H, Liu SF, Wang LS, Gong RZ, Li CT  |
|        |  |
| 11074  | Bone marrow metastatic neuroendocrine carcinoma with unknown primary site: A case report and review of the literature                                    |
|        | Shi XB, Deng WX, Jin FX  |
| 11082  | Child with adenylosuccinate lyase deficiency caused by a novel complex heterozygous mutation in the <i>ADSL</i> gene: A case report                      |
|        | Wang XC, Wang T, Liu RH, Jiang Y, Chen DD, Wang XY, Kong QX  |
| 11090  | Recovery of brachial plexus injury after bronchopleural fistula closure surgery based on electrodiagnostic study: A case report and review of literature |
|        | Go YI, Kim DS, Kim GW, Won YH, Park SH, Ko MH, Seo JH  |
| 11101  | Severe <i>Klebsiella pneumoniae</i> pneumonia complicated by acute intra-abdominal multiple arterial thrombosis and bacterial embolism: A case report    |
|        | Bao XL, Tang N, Wang YZ  |
| 11111  | Spontaneous bilateral femur neck fracture secondary to grand mal seizure: A case report  |
|        | Senocak E  |
| 11116  | Favorable response after radiation therapy for intraductal papillary mucinous neoplasms manifesting as acute recurrent pancreatitis: A case report       |
|        | Harigai A, Kume K, Takahashi N, Omata S, Umezawa R, Jingu K, Masamune A  |
| 11122  | Acute respiratory distress syndrome following multiple wasp stings treated with extracorporeal membrane oxygenation: A case report                       |
|        | Cai ZY, Xu BP, Zhang WH, Peng HW, Xu Q, Yu HB, Chu QG, Zhou SS   |
| 11128  | Morphological and electrophysiological changes of retina after different light damage in three patients:<br>Three case reports                           |
|        | Zhang X, Luo T, Mou YR, Jiang W, Wu Y, Liu H, Ren YM, Long P, Han F  |
| 11139  | Perirectal epidermoid cyst in a patient with sacrococcygeal scoliosis and anal sinus: A case report  |
|        | Ji ZX, Yan S, Gao XC, Lin LF, Li Q, Yao Q, Wang D  |
|        |  |



| <b>0</b> | World Journal of Clinical Cases  |
|----------|--|
| Conten   | Thrice Monthly Volume 10 Number 30 October 26, 2022  |
| 11146    | Synchronous gastric cancer complicated with chronic myeloid leukemia (multiple primary cancers): A case report   |
|          | Zhao YX, Yang Z, Ma LB, Dang JY, Wang HY   |
| 11155    | Giant struma ovarii with pseudo-Meigs' syndrome and raised cancer antigen-125 levels: A case report <i>Liu Y, Tang GY, Liu L, Sun HM, Zhu HY</i>   |
| 11162    | Longest survival with primary intracranial malignant melanoma: A case report and literature review <i>Wong TF, Chen YS, Zhang XH, Hu WM, Zhang XS, Lv YC, Huang DC, Deng ML, Chen ZP</i> |
| 11172    | Spontaneous remission of hepatic myelopathy in a patient with alcoholic cirrhosis: A case report<br>Chang CY, Liu C, Duan FF, Zhai H, Song SS, Yang S                                    |
| 11178    | Cauda equina syndrome caused by the application of DuraSeal™ in a microlaminectomy surgery: A case report  |
|          | Yeh KL, Wu SH, Fuh CS, Huang YH, Chen CS, Wu SS  |
| 11185    | Bioceramics utilization for the repair of internal resorption of the root: A case report <i>Riyahi AM</i>  |
| 11190    | Fibrous hamartoma of infancy with bone destruction of the tibia: A case report   |
|          | Qiao YJ, Yang WB, Chang YF, Zhang HQ, Yu XY, Zhou SH, Yang YY, Zhang LD  |
| 11198    | Accidental esophageal intubation <i>via</i> a large type C congenital tracheoesophageal fistula: A case report <i>Hwang SM, Kim MJ, Kim S, Kim S</i>                                     |
| 11204    | Ventral hernia after high-intensity focused ultrasound ablation for uterine fibroids treatment: A case report <i>Park JW, Choi HY</i>  |
|          | LETTER TO THE EDITOR   |
| 11210    | C-Reactive protein role in assessing COVID-19 deceased geriatrics and survivors of severe and critical   |

illness Nori W



#### Contents

Thrice Monthly Volume 10 Number 30 October 26, 2022

#### **ABOUT COVER**

Editorial Board Member of World Journal of Clinical Cases, Rajeev Gurunath Redkar, FRCS, FRCS (Ed), FRCS (Gen Surg), MBBS, MCh, MS, Dean, Professor, Surgeon, Department of Pediatric Surgery, Lilavati Hospital and Research Centre, Mumbai 400050, Maharashtra, India. rajeev.redkar@gmail.com

#### **AIMS AND SCOPE**

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

#### **INDEXING/ABSTRACTING**

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

#### **RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: Ying-Yi Yuan; Production Department Director: Xu Guo; Editorial Office Director: Jin-Lei Wang.

| NAME OF JOURNAL   | INSTRUCTIONS TO AUTHORS  |
|---|--|
| World Journal of Clinical Cases   | https://www.wjgnet.com/bpg/gerinfo/204                           |
| <b>ISSN</b>   | GUIDELINES FOR ETHICS DOCUMENTS                                  |
| ISSN 2307-8960 (online)   | https://www.wignet.com/bpg/GerInfo/287                           |
| LAUNCH DATE   | GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH                    |
| April 16, 2013  | https://www.wignet.com/bpg/gerinfo/240                           |
| FREQUENCY   | PUBLICATION ETHICS   |
| Thrice Monthly  | https://www.wjgnet.com/bpg/GerInfo/288                           |
| <b>EDITORS-IN-CHIEF</b><br>Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja<br>Hyeon Ku | PUBLICATION MISCONDUCT<br>https://www.wjgnet.com/bpg/gerinfo/208 |
| EDITORIAL BOARD MEMBERS   | ARTICLE PROCESSING CHARGE  |
| https://www.wjgnet.com/2307-8960/editorialboard.htm   | https://www.wjgnet.com/bpg/gerinfo/242                           |
| PUBLICATION DATE  | STEPS FOR SUBMITTING MANUSCRIPTS                                 |
| October 26, 2022  | https://www.wjgnet.com/bpg/GerInfo/239                           |
| COPYRIGHT   | ONLINE SUBMISSION  |
| © 2022 Baishideng Publishing Group Inc  | https://www.f6publishing.com                                     |

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



W J C C World Journal C Clinical Cases

# World Journal of

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2022 October 26; 10(30): 10967-10983

DOI: 10.12998/wjcc.v10.i30.10967

ISSN 2307-8960 (online)

META-ANALYSIS

# Impact of being underweight on peri-operative and post-operative outcomes of total knee or hip arthroplasty: A meta-analysis

Yun-Ping Ma, Qiu Shen

Specialty type: Orthopedics

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

#### Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B, B Grade C (Good): C Grade D (Fair): 0 Grade E (Poor): 0

P-Reviewer: Mahmoud MZ, Saudi Arabia; Solarino G, Italy; Velá zquez-Saornil J, Spain

Received: March 14, 2022 Peer-review started: March 14, 2022 First decision: June 16, 2022 Revised: July 6, 2022 Accepted: September 16, 2022 Article in press: September 16, 2022 Published online: October 26, 2022



Yun-Ping Ma, Qiu Shen, Department of Orthopedics, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, Huzhou 313000, Zhejiang Province, China

Corresponding author: Qiu Shen, RN, Nurse, Department of Orthopedics, Huzhou Central Hospital, Affiliated Central Hospital of Huzhou University, No. 1558 Sanhuan North Road, Huzhou 313000, Zhejiang Province, China. squ16871687@163.com

## Abstract

#### BACKGROUND

Many systematic reviews have focused on assessing the effect of body mass index (BMI) on the outcomes and complications associated with total hip arthroplasty (THA) and total knee arthroplasty (TKA), but primarily dealt with obesity compared to normal weight (NW). None of these reviews attempted to assess the effect of low BMI or underweight (UW) compared to NW in patients undergoing THA or TKA.

#### AIM

This review aims to compare specific operative outcomes such as operation duration, length of hospital stay, and post-operative complications including mortality, infections, deep vein thrombosis, etc. along with re-hospitalization and reoperation rates between UW and NW patients undergoing THA, TKA or both.

#### **METHODS**

An electronic search was performed in PubMed, Scopus, Excerpta Medica database (EMBASE), Web of Science (WoS), and Cochrane Central Register of Controlled Trials (CENTRAL) along with a manual search. The quality of the studies was assessed using the Newcastle-Ottawa scale for cohort studies. The data were subjected to both qualitative and quantitative analysis.

#### RESULTS

Thirteen retrospective and five prospective cohort studies were included. The quality of included studies was assessed to be good to fair. The length of hospital stay after TKA or THA was found to be significantly higher for UW patients when compared to NW patients, with a mean difference: 0.39 95%CI: [0.06, 0.72], P = 0.02 (in days). Studies presenting both THA and TKA together as total joint arthroplasty showed an increased incidence of mortality in patients treated with THA or TKA alone, Odds ratio: 4.18 95%CI: [2.88, 6.07]. A higher incidence of post-ope-rative complications was also observed in UW patients undergoing THA.



#### CONCLUSION

UW patients undergoing THA or TKA had a higher incidence of post-operative complications and were associated with a higher readmission rate. Moreover, UW patients were associated with an increased incidence of mortality in the studies that reported THA and TKA together.

Key Words: Underweight; Total knee arthroplasty; Total hip arthroplasty; Systematic review; Meta-analysis

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Many systematic reviews have focused on assessing the effect of body mass index (BMI) on the outcomes and complications associated with total hip arthroplasty (THA) and total knee arthroplasty (TKA), but primarily dealt with obesity compared to normal weight (NW) patients. None of these reviews attempted to assess the effect of low BMI or underweight (UW) compared to NW in patients undergoing THA or TKA. The present analysis found that UW patients undergoing THA or TKA had with a higher incidence of post-operative complications and were associated with a higher readmission rate.

Citation: Ma YP, Shen Q. Impact of being underweight on peri-operative and post-operative outcomes of total knee or hip arthroplasty: A meta-analysis. *World J Clin Cases* 2022; 10(30): 10967-10983 URL: https://www.wjgnet.com/2307-8960/full/v10/i30/10967.htm DOI: https://dx.doi.org/10.12998/wjcc.v10.i30.10967

#### INTRODUCTION

Body mass index (BMI) plays a pivotal role in predicting the outcomes and associated complications after total hip arthroplasty (THA) and total knee arthroplasty (TKA)[1]. BMI in the population is mainly divided into 5 categories: Underweight (score of < 18.5); normal weight (18.5-24.9); overweight (25-29.9); obese (30-34.9) and morbidly obese (> 40). This score is defined by weight in kilograms per square meter of height[2].

Extreme values of BMI are regarded as a risk factor for various systemic diseases such as diabetes, cardiovascular diseases, pulmonary diseases, dementia, and notable osteoarthritis in the elderly[3]. Obesity has already been proved to be associated with poor clinical outcomes, and lower success rates in patients undergoing total joint arthroplasty (TJA)[4,5]. Obese patients present with a higher incidence of infection, and complications compared to normal weight (NW) individuals[6]. However, the results were conflicting. Despite this negative relation between obesity and the success of THA or TKA, some studies established that no difference was observed between obese and non-obese patients in terms of clinical outcomes, survival rate, and complications[7-9].

Underweight (UW) patients suffer from poor nutrition, anemia, vitamin deficiencies, and most importantly osteoporosis due to calcium and vitamin D deficiency. Osteoporosis is a major risk factor for patients with osteoarthritis requiring THA or TKA. The understanding of prognosis post-THA or TKA in UW patients is less studied and not clearly understood. The literature which focused on evaluating the effect of BMI also showed the outcomes of UW patients undergoing arthroplasty. It was interesting to note that UW patients may also lead to poor post-operative outcomes, including increased rates of post-operative infection, transfusion, cardiovascular events, and renal complications[10,11]. UW patients have also been shown to potentially delay mobilization, increase length of stay and hospital expenditures[12,13]. However, the evidence is scarce, and very few studies directly attempted to assess the effect of UW compared to NW individuals.

Many systematic reviews have focused on assessing the effect of BMI on the outcomes and complications associated with TJA[14-17], but primarily dealt with obesity compared to NW. None of the reviews attempted to assess the effect of low BMI or UW in patients undergoing THA or TKA. The risk of UW patients undergoing TJA is debatable and no substantial evidence has been put forth. This is the first review to compare operative and post-operative complications between UW and NW patients undergoing THA or TKA. The objective of this review is to compare the specific operative outcomes such as operation duration, length of hospital stay, and post-operative complications including mortality, infections, deep vein thrombosis (DVT), *etc.* along with rehospitalization and reoperation rates between UW and NW patients undergoing THA, TKA or both.

Zaishideng® WJCC | https://www.wjgnet.com

| Table 1 Se | earch strategy  |         |
|------------|---|---------|
| Database   | Search strategy   | Results |
| PubMed     | (((("Under-weight") OR (Low body mass index)) OR (malnourished)) AND (((("total knee arthroplasty"[All Fields]) OR ("total hip arthroplasty"[All Fields])) OR ("total joint arthroplasty"[All Fields])) OR ("total knee replacement"[All Fields]))) AND (((((mortality) OR (complications))) OR (readmissions)) OR (rehospitalization)) OR (length of hospital stay)) | 243     |
| CENTRAL    | #1 Underweight  | 25      |
|            | #2 Low body mass index  |         |
|            | #3 Malnourished   |         |
|            | #4 #1 OR #2 OR #3   |         |
|            | #5 MeSH descriptor: [Arthroplasty, Replacement, Knee] explode all trees   |         |
|            | #6 MeSH descriptor: [Arthroplasty, Replacement, Hip] explode all trees  |         |
|            | #7 MeSH descriptor: [Arthroplasty, Replacement] explode all trees   |         |
|            | #8 #5 OR #6 OR #7   |         |
|            | #9 #4 AND #8  |         |
| EMBASE     | (((("Under-weight") OR (Low body mass index)) OR (malnourished)) AND (((("total knee arthroplasty"[All Fields]) OR ("total hip arthroplasty"[All Fields])) OR ("total joint arthroplasty"[All Fields])) OR ("total knee replacement"[All Fields]))) AND (((((mortality) OR (complications)) OR (readmissions)) OR (rehospitalization)) OR (length of hospital stay))  | 67      |
| WoS        | TS=("under-weight" OR "low body mass index" OR malnourished ) AND TS=("Total knee arthroplasty" OR " Total joint arthroplasty" OR "Total hip arthroplasty") AND TS=(mortality OR complications OR rehospitalization OR readmissions OR "length of hospital stay" )  | 110     |
| SCOPUS     | ALL ("under-weight" OR "low body mass index" OR malnourished) AND ALL ("Total knee arthroplasty" OR " Total joint arthroplasty" OR "Total hip arthroplasty") AND ALL (mortality OR complications OR rehospitalization OR re-admissions OR "length of hospital stay")  | 261     |

MeSH: Medical subheadings; TS: Topic; WoS: Web of science.

#### MATERIALS AND METHODS

This systematic review and meta-analysis were performed according to the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines[18]. The protocol for conducting this review was predefined and employed to conduct the systematic review efficiently in a smooth manner. Ethics approval was not required for this review.

#### Research question

What is the impact of UW compared to NW on operative outcomes, rehospitalization and reoperation rates, and post-operative complications in patients undergoing THA or TKA?

The following PICO strategy was employed to formulate the research question and search strategy to identify eligible articles: Patients (P): Patients undergoing THA or TKA; Exposure (E): UW patients with BMI < 18.5 kg/m<sup>2</sup>; Comparison (C): NW patients with BMI between 18.5-24.9 kg/m<sup>2</sup>; Outcome (O): Operation duration (in min), length of hospital stay (in days), and post-operative complications such as mortality, infections, DVT, pulmonary embolism, genito-urinary complications, dislocation/ subluxation, fracture along with rehospitalization and reoperation rates expressed as a proportion (event/total); Study design (S): All observational studies comparing outcomes of UW vs NW patients undergoing THA or TKA or TJA.

#### Search strategy

A comprehensive search strategy was developed to identify the relevant articles to answer the question. An electronic search was performed in PubMed, Scopus, Excerpta Medica database (EMBASE), Web of Science (WoS), and Cochrane Central Register of Controlled Trials (CENTRAL). The search strategy was framed using the following relevant keywords: underweight; "low body mass index"; malnourished; "Total knee arthroplasty"; "Total joint arthroplasty"; "Total hip arthroplasty"; mortality; complications; rehospitalization; readmissions; "length of hospital stay". The details of the search strategy are provided in Table 1. No limits or restrictions were applied to the electronic search. The last electronic search was carried out in June 2021. An additional manual search was also carried out in peer-reviewed relevant journals such as the Journal of Orthopedics; Journal of Arthroplasty; Journal of Orthopedic Surgery and Research; and Journal of Knee Surgery, Sports Traumatology, and Arthroscopy. The reference list of previously conducted relevant systematic reviews and other relevant studies were screened for possible inclusion of eligible articles. The identified reports along with electronic search results were imported



into a citation manager (ENDNOTE) in order to discard duplicates obtained from multiple databases.

#### Study selection

The reports were screened by two independent reviewers based on the below-mentioned inclusion and exclusion criteria:

Inclusion criteria: All studies comparing outcomes of UW vs NW patients undergoing THA or TKA or TJA. Studies reporting outcomes such as operation duration, length of hospital stay, and post-operative complications including mortality, infections, DVT, pulmonary embolism, genito-urinary complications, dislocation/subluxation, fracture along with rehospitalization and reoperation rates. Studies attaining a minimum score of 7 assessed using the Newcastle-Ottawa scale (NOS) of quality assessment were included.

Exclusion criteria: Studies published in other than the English language. Studies not reporting relevant outcomes. Studies recruiting patients with other systemic diseases, and immune-compromised patients. Studies with a score less than 7 assessed using the NOS of quality assessment were excluded.

#### Data extraction

Data extraction was performed by two independent reviewers (YM, and QS) using an Excel spreadsheet. The demographic characteristics and details of outcomes such as operation duration, length of hospital stay, and post-operative complications including mortality, infections, DVT, pulmonary embolism, genito-urinary complications, dislocation/subluxation, fracture along with rehospitalization and reoperation rates were extracted. The authors were contacted by email for clarification on missing data or unclear information.

#### Data synthesis

The extracted data were subjected to both qualitative and quantitative analysis. The outcomes which could not be combined for quantitative analysis were summarized. The continuous data of the extracted outcomes were expressed as mean and standard deviation. The dichotomous outcomes were expressed as an absolute number of events, ratio, and proportion. The outcome effect was calculated between UW and NW patients as the mean difference for continuous outcomes and odds ratio for dichotomous outcomes. The quantitative data were subjected to meta-analysis using RevMan v 5.4 software. The meta-analysis was carried out only if two or more studies with similar outcomes were available. A P value < 0.05 for assessing the outcome effect was considered significant. A random effect model was chosen if the included studies presented a varied population. The heterogeneity among the studies was assessed using  $l^2$  statistics. The heterogeneity was considered low if the  $l^2$  value was found to be < 40%, moderate for a value of 40%-70%, and high for a value more than 70%. The studies presented the data on THA or TKA alone and reported both THA and TKA data together. Hence, a sub-group analysis was carried out based on the type of joint arthroplasty reported. For outcomes such as mortality, a subgroup analysis was carried out based on the time frame.

#### Quality of included studies

The methodological quality of included studies was assessed by two independent reviewers using the NOS. The NOS consists of eight items grouped into three categories, namely: selection, comparability, and outcome. A scoring system, ranging from zero to nine stars, was used to classify the quality of the study being reviewed. Each included study received the following categorical scores representing its quality: good (three or four scores in the selection domain AND one or two scores in the comparability domain AND two or three scores in the outcome domain), fair (two scores in selection domain AND one or two scores in comparability domain AND two or three scores in outcome domain) or poor (zero or one score in selection domain OR zero score in comparability domain OR zero or one score in outcome domain).

#### RESULTS

A total of eighteen studies[10,11,19-34] were included in this review. Twenty-two eligible studies[4,35-37] were screened from a pool of 671 records identified from both electronic and manual searches, purely based on title and abstract. The inclusion and exclusion criteria were strictly applied to carry out the full-text assessment of eligible studies. Finally, eighteen studies were deemed inclusive after satisfying the pre-defined criteria. The complete study selection process is described in Figure 1, and the detailed search strategy employed in all databases is provided in Table 1.

#### Demographic characteristics

Thirteen retrospective cohort studies[10,11,19-23,25,26,28,29,31,33] and five prospective cohort studies [24,27,30,32,34] were included. The studies included a total of 1136506 subjects undergoing TKA or THA





DOI: 10.12998/wjcc.v10.i30.10967 Copyright ©The Author(s) 2022.



with a mean age of 65.32 years. The subjects comprised 469387 males and 667119 females. Out of these recruited subjects undergoing TKA or THA, 213028 subjects were NW individuals with a BMI between 18.5 and 24.9, and only 10785 subjects were UW individuals with a BMI < 18.5. Sixteen studies [10,19,21-34] assessed the outcomes for THA and nine studies[11,19,20,23,26,28,30,31,33] for TKA. Only seven studies[19,23,26,28,30,31,33] presented data with both THA and TKA. The demographic characteristics of the included studies are provided in Table 2. The quality of studies assessed using NOS was found to be good to fair quality. Details of the Newcastle-Ottawa scoring criteria according to domains were well presented and are shown in Table 3.

#### Meta-analysis

**Operation duration (in min):** The operation duration between UW (n = 2102) and NW (n = 55701) patients undergoing THA or TKA, was found to be not significantly different with MD: 1.66 95% CI: [-1.89, 5.21, P = 0.36. A subgroup analysis was carried out based on the type of procedure to analyze the heterogeneity ( $l^2 = 75\%$ ). No difference in the result was observed in patients undergoing THA MD: 0.73 95%CI: [-3.31, 4.77]. *P* = 0.72 and TJA MD: 2.54 95%CI: [-3.59, 8.66], *P* = 0.42 (Figure 2).

Length of hospital stay (in days): The length of hospital stay after arthroplasty was found to be significantly higher for UW patients (n = 4555), when compared to NW patients (n = 58890). MD: 0.39 95% CI: [0.06, 0.72], P = 0.02,  $I^2 = 81\%$ .

The subgroup analysis showed no significant differences between UW and NW patients undergoing THA or TKA. However, in patients undergoing both THA and TKA, the length of hospital stay was found to be significantly higher for UW patients (n = 2207) MD: 0.76 95% CI: [0.43, 1.09], P < 0.0001. Low heterogeneity was also observed with an  $I^2$  value of 31% (Figure 3).

30-90-day readmission rate: No significant difference in readmission rate was observed between UW and NW patients undergoing THA or TKA with OR: 1.42 95%CI: [0.71, 2.87], P = 0.32;  $I^2 = 36\%$ . No subgroup differences were observed. UW patients (n = 408) undergoing THA presented with an increased OR: 1.75 95% CI: [0.58, 5.27], P = 0.32,  $I^2 = 49\%$  (not significant) of 30-90 d readmission compared to NW patients (Figure 4).

Re-operation rate: No significant difference in reoperation rate was observed between UW and NW patients undergoing THA with OR: 1.22 95%CI: [0.43, 3.42], P = 0.71; P = 0.%. No subgroup differences were observed (Figure 5).



| Table 0.0h  |                 | f in a local and a | . A     |  |
|-------------|-----------------|--------------------|---------|--|
| l able 2 Ch | aracteristics c | of included s      | studies |  |

| Ref.                                     | Type of<br>study | Total<br>participants | Age<br>(mean) | Follow up<br>time | Gender (F/M)  | Treatment      | Groups                | Number of<br>participants per<br>group |
|--|------------------|-----------------------|---------------|-------------------|---------------|----------------|-----------------------|--|
| Hartford <i>et al</i> [20],              | Retrospective    | 1774                  | 67.08         | 3 mo              | 1078/696      | THA            | Underweight           | 13                                     |
| 2020                                     |                  |                       |               |                   |               |                | Normal                | 463                                    |
| Katakam <i>et al</i> [18],               | Retrospective    | 4802                  | 65.9          | 2 yr              | 2698/2104     | THA and        | Underweight2          | 85                                     |
| 2021                                     |                  |                       |               |                   |               | IKA            | Normal                | 821                                    |
| Kwon <i>et al</i> [19],                  | Retrospective    | 118                   | 70.75         | 2 yr              | 118/0         | TKA            | Underweight           | 41                                     |
| 2020                                     |                  |                       |               |                   |               |                | Normal                | 77                                     |
| Sloan <i>et al</i> [22], 2019            | Retrospective    | 378775                | 65.7          | 1 mo              | 224912/153863 | THA and        | Underweight           | 1846                                   |
|  |                  |                       |               |                   |               | IKA            | Normal                | 51130                                  |
| Hung <i>et al</i> [24],                  | Retrospective    | 1565                  | 54.46         | 1 mo              | 830/735       | THA            | Underweight           | 56                                     |
| 2019                                     |                  |                       |               |                   |               |                | Normal                | 697                                    |
| Sayed-Noor <i>et al</i>                  | Prospective      | 83146                 | 69            | 2 yr (90 d        | 47210/35936   | THA            | Underweight           | 579                                    |
| [23], 2019                               |                  |                       |               | mortanty)         |               |                | Normal                | 25718                                  |
| Woo <i>et al</i> [21], 2019              | Retrospective    | 3672                  | 78.06         | 1 yr              | 2620/1007     | THA            | Underweight           | 332                                    |
|  |                  |                       |               |                   |               |                | Normal                | 750                                    |
| Dowsey <i>et al</i> [27], 2018           | Retrospective    | 172767                | 67.65         | 5 yr              | 104742/68024  | THA and<br>TKA | TKA +<br>Underweight  | 268                                    |
|  |                  |                       |               |                   |               |                | TKA + Normal          | 13261                                  |
|  |                  |                       |               |                   |               |                | THA<br>+Underweight   | 492                                    |
|  |                  |                       |               |                   |               |                | THA + Normal          | 13226                                  |
| Shohat <i>et al</i> [25],                | Retrospective    | 18173                 | 61.33         | 3 mo              | 9986/8187     | THA and        | Underweight           | 96                                     |
| 2018                                     |                  |                       |               |                   |               | IKA            | Normal                | 3266                                   |
| Zusmanovich <i>et al</i>                 | Retrospective    | 840                   | 72.05         | 1 mo              | 660/180       | THA            | Underweight           | 301                                    |
| [9], 2018                                |                  |                       |               |                   |               |                | Normal                | 539                                    |
| Mouchti <i>et al</i> [26],               | Prospective      | 415598                | 67.75         | 3 mo              | 246780/168818 | THA            | Underweight           | 3588                                   |
| 2018                                     |                  |                       |               |                   |               |                | Normal                | 86336                                  |
| Manrique <i>et al</i> [10],              | Retrospective    | 108                   | 69.7          | 3.8 yr            | 93/24         | TKA            | Underweight           | 27                                     |
| 2017                                     |                  |                       |               |                   |               |                | Normal                | 81                                     |
| Anoushiravani <i>et al</i><br>[30], 2016 | Retrospective    | 4864                  | 70.54         | NA                | 4064/800      | THA and<br>TKA | THA +<br>Underweight1 | 1762                                   |
|  |                  |                       |               |                   |               |                | THA + Normal          | 1787                                   |
|  |                  |                       |               |                   |               |                | TKA +<br>Underweight  | 670                                    |
|  |                  |                       |               |                   |               |                | TKA + Normal          | 645                                    |
| Husted <i>et al</i> [29], 2016           | Prospective      | 13730                 | NR            | 3 mo              | NR            | THA and<br>TKA | TKA +<br>Underweight  | 29                                     |
|  |                  |                       |               |                   |               |                | TKA + Normal          | 1250                                   |
|  |                  |                       |               |                   |               |                | THA +<br>Underweight  | 77                                     |
|  |                  |                       |               |                   |               |                | THA + Normal          | 2396                                   |
| Shaparin <i>et al</i> [28],              | Retrospective    | 880                   | 61.33         | 1 mo              | 541/339       | THA            | Underweight           | 17                                     |
| 2016                                     |                  |                       |               |                   |               |                | Normal                | 168                                    |
|  |                  |                       |               |                   |               |                |                       |  |



Baisbideng® WJCC | https://www.wjgnet.com

| Zhao <i>et al</i> [ <mark>31</mark> ], 2014 | Prospective   | 236   | 36.5  | NA      | 34/202      | THA     | Underweight | 91   |
|---|---------------|-------|-------|---------|-------------|---------|-------------|------|
|   |               |       |       |         |             |         | Normal      | 145  |
| Thornqvist <i>et al</i>                     | Retrospective | 34744 | 70.6  | 1 mo    | 20438/14306 | THA and | Underweight | 353  |
| [32], 2014                                  |               |       |       |         |             | IKA     | Normal      | 9859 |
| Zhang <i>et al</i> [33],                    | Prospective   | 714   | 62.17 | 5-20 yr | 315/399     | THA     | Underweight | 62   |
| 2012  |               |       |       |         |             |         | Normal      | 413  |

<sup>1</sup>Underweight < 19.5 kg/m<sup>2</sup>.

<sup>2</sup>Underweight < 20 kg/m<sup>2</sup>.

Underweight < 18.5 kg/m<sup>2</sup>, Normal – 18.5 – 24.9 kg/m<sup>2</sup>. THA: Total hip arthroplasty; TKA: Total knee arthroplasty; NA: Not available; NR: Not reported, Ref: reference; mo: Month; yr: Year; F: Female; M: Male

|   |                           | uw                        |                     |                                  | NW    |       |         | Mean difference      |               | Mean difference                      |
|---|---------------------------|---------------------------|---------------------|----------------------------------|-------|-------|---------|----------------------|---------------|--------------------------------------|
| Study or subgroup   | Mean                      | SD                        | Total               | Mean                             | SD    | Total | Weight  | IV, random, 95%CI    | Year          | IV, random, 95%Cl                    |
| 2.1.1 THA   |                           |                           |                     |                                  |       |       |         |                      |               |                                      |
| Zhao et al., 2014   | 60                        | 11                        | 91                  | 61                               | 8     | 145   | 26.00%  | -1.00 [-3.61, 1.61]  | 2014          | -                                    |
| Hung et al., 2019   | 74.39                     | 18.54                     | 56                  | 69.82                            | 17.59 | 697   | 18.80%  | 4.57 [-0.46, 9.60]   | 2019          | <b></b>                              |
| Hartford et al., 2020   | 102.1                     | 15.4                      | 13                  | 104                              | 56.3  | 463   | 9.10%   | -1.90 [-11.72, 7.92] | 2020          |                                      |
| Subtotal (95%CI)  |                           |                           | 160                 |                                  |       | 1305  | 54.00%  | 0.73 [-3.31, 4.77]   |               | •                                    |
| Heterogeneity: Tau <sup>2</sup> =                             | 6.21; Chi <sup>2</sup>    | = 3.88, df                | = 2 ( <i>P</i> = 0. | 14); /² = 48                     | %     |       |         |                      |               | T T                                  |
| Test for overall effect:                                      | Z = 0.35 (/               | P = 0.72)                 |                     |                                  |       |       |         |                      |               |                                      |
| 2.1.2 THA and TKA   | <i></i>                   |                           |                     | ~~                               | 2.2   | 2255  | 10.000/ |                      |               |                                      |
| Shohat et al., 2018   | 65                        | 24                        | 96                  | 66                               | 28    | 3266  | 19.20%  | -1.00 [-5.90, 3.90]  | 2018          |                                      |
| Sloan et al., 2019  | 98.6                      | 49.7                      | 1846                | 93.3                             | 44.9  | 51130 | 26.80%  | 5.30 [3.00, 7.60]    | 2019          |                                      |
| Subtotal (95%CI)  |                           |                           | 1942                |                                  |       | 54396 | 46.00%  | 2.54 [-3.59, 8.66]   |               |                                      |
| Heterogeneity: Tau <sup>2</sup> =<br>Test for overall effect: | 16.04; Chi<br>Z = 0.81 (/ | i² = 5.21, d<br>P = 0.42) | f = 1 (P = 0        | 0.02); <i>I</i> <sup>2</sup> = 8 | 1%    |       |         |                      |               |                                      |
| Total (95%CI)   |                           |                           | 2102                |                                  |       | 55701 | 100.00% | 1.66 [-1.89, 5.21]   |               | •                                    |
| Heterogeneity: Tau <sup>2</sup> =                             | 10.86; Chi                | i <sup>2</sup> = 15.91,   | df = 4 (P =         | 0.003); /2 :                     | = 75% |       |         |                      |               |                                      |
| Test for overall effect:                                      | Z = 0.91 (/               | P = 0.36)                 |                     |                                  |       |       |         |                      |               | -20 -10 0 10 20                      |
| Test for subgroup diffe                                       | erences; Cl               | hi² = 0.23,               | df = 1 ( <i>P</i> = | 0.63), <i>I</i> <sup>2</sup> =   | 0%    |       |         |                      |               | NW UW                                |
|   |                           |                           |                     |                                  |       |       |         | DOI: 10.12998        | /wjcc.v10.i30 | .10967 Copyright ©The Author(s) 2022 |

Figure 2 Operation duration. CI: Confidence intervals; P: Heterogeneity; IV: Inverse variance; NW: Normal weight; SD: Standard deviation; THA: Total hip arthroplasty; TKA: Total knee arthroplasty; UW: Underweight.

> **Post-operative mortality:** UW patients (*n* = 6880) had higher odds of post-operative mortality than NW patients (126040) with OR: 2.20 95% CI: [1.43, 3.37], P = 0.0003. However, a high heterogeneity with an  $I^2$ value of 91% was observed. Following subgroup analysis, it was found that studies reporting THA and TKA together showed an increased incidence of mortality in UW patients (n = 438) OR: 4.18 95%CI: [2.88, 6.07], P < 0.0001 with  $I^2 = 0\%$ . Although not significant, the incidence of post-operative mortality was less likely to be observed in UW patients, compared to NW patients (Figure 6).

> A subgroup analysis carried out based on timeframe showed higher 31-365 d mortality in UW patients with OR: 2.35 95%CI: [1.31, 3.54], P < 0.0001,  $I^2 = 29\%$ , than NW patients (Supplementary Figure 1).

> Post-operative infection: No significant difference in the incidence of post-operative infection was observed between UW (n = 2955) and NW patients (n = 8261) undergoing THA or TKA with OR: 0.68 95% CI: [0.20, 16.29], P = 0.54;  $I^2 = 51\%$ . No subgroup differences were observed (Figure 7). The incidence of post-operative infection was lower (not significant) in UW patients, compared to NW patients.

> Total complications: No significant difference in hazard ratios computing total complications was observed between UW and NW patients. The incidence of total or overall complications observed between the two groups of patients undergoing arthroplasty was similar with HR: 1.27 95% CI: [0.50, 3.22], P = 0.61,  $I^2 = 27\%$  (Figure 8).

> **Post-operative complications in patients undergoing THA:** UW patients (*n* = 31619) showed higher odds for the incidence of post-operative complications with OR: 1.44 95% CI: [1.10, 1.88], P = 0.008, P =58%, in patients undergoing THA. Subsequently, a significantly higher incidence of DVT and cardiac infarction among the post-operative complications were observed in UW patients undergoing THA (Figure 9).

> Post-operative complications in patients undergoing TKA: No significant difference in post-operative infection, DVT and pulmonary embolism was observed in UW (n = 2134) compared to NW (n = 3424) patients undergoing TKA with OR: 1.88 95% CI: [0.34, 10.41], *P* = 0.47, *I*<sup>2</sup> = 56% (Figure 10).



#### Table 3 Newcastle-Ottawa Scale scores for assessing the quality of included studies

|  | Selection                                      |  |                              |  | Comparability                         | Outcome                  |  |                       |       |
|--|--|--|------------------------------|--|---------------------------------------|--------------------------|--|-----------------------|-------|
| Ref.   | Representativeness<br>of the exposed<br>cohort | Selection<br>of the<br>non-<br>exposed<br>cohort | Ascertainment<br>of exposure | Demonstration<br>that outcome<br>of interest | Basis of the<br>design or<br>analysis | Assessment<br>of outcome | Follow-up<br>long<br>enough<br>for<br>outcomes | Adequate<br>follow up | Total |
| Hartford <i>et al</i> [20], 2020                       | 1  | 1  | 0                            | 1  | 1                                     | 1                        | 1  | 1                     | 7     |
| Katakam <i>et al</i><br>[ <mark>18]</mark> , 2021      | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Kwon <i>et al</i><br>[ <b>19</b> ], 2020               | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Sloan <i>et al</i> [ <mark>22</mark> ],<br>2019        | 1  | 1  | 0                            | 1  | 1                                     | 1                        | 1  | 1                     | 7     |
| Hung <i>et al</i><br>[ <mark>24</mark> ], 2019         | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Sayed-Noor et al[23], 2019                             | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Woo <i>et al</i> [ <mark>21</mark> ],<br>2019          | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Dowsey <i>et al</i><br>[27], 2018                      | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Shohat <i>et al</i><br>[ <mark>25]</mark> , 2018       | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Zusmanovich<br>et al[9], 2018                          | 1  | 1  | 1                            | 1  | 2                                     | 1                        | 1  | 1                     | 9     |
| Mouchti <i>et al</i><br>[ <mark>26]</mark> , 2018      | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Manrique <i>et al</i><br>[ <mark>10]</mark> , 2017     | 1  | 1  | 0                            | 0  | 1                                     | 1                        | 1  | 1                     | 6     |
| Anoushiravani<br><i>et al</i> [ <mark>30], 2016</mark> | 1  | 1  | 0                            | 1  | 1                                     | 1                        | 1  | 1                     | 7     |
| Husted <i>et al</i><br>[29], 2016                      | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Shaparin <i>et al</i><br>[ <mark>28]</mark> , 2016     | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Zhao <i>et al</i> [ <mark>31</mark> ],<br>2014         | 1  | 1  | 0                            | 1  | 1                                     | 1                        | 1  | 1                     | 7     |
| Thornqvist <i>et al</i> [32], 2014                     | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |
| Zhang <i>et al</i> [33], 2012                          | 1  | 1  | 1                            | 1  | 1                                     | 1                        | 1  | 1                     | 8     |

#### DISCUSSION

This systematic review and meta-analysis included thirteen retrospective and five prospective cohort studies to compare UW and NW patients undergoing THA or TKA or TJA in terms of specific outcomes such as operation duration, length of hospital stay, and post-operative complications including mortality, infections, DVT, pulmonary embolism, genito-urinary complications, dislocation/sub-luxation, fracture along with rehospitalization and reoperation rates. The quality of the studies included was good to fair. UW patients undergoing THA or TKA had a higher incidence of post-operative complications and readmission rates. Moreover, studies reporting THA and TKA were associated with an increased incidence of mortality. Also, a higher incidence of DVT and cardiac infarction was evident among the post-operative complications in UW patients undergoing THA. No difference in post-operative complications was found in UW patients undergoing TKA.

Baisbidena® WJCC | https://www.wjgnet.com

|   |                         | uw                   |                   |                                  | NW   |       |         | Mean difference        |             | Mean difference                                |
|---|-------------------------|----------------------|-------------------|----------------------------------|------|-------|---------|------------------------|-------------|--|
| Study or subgroup                       | Mean                    | SD                   | Total             | Mean                             | SD   | Total | Weight  | IV, random, 95%CI      | Year        | IV, random, 95%CI                              |
| 2.1.1 THA                               |                         |                      |                   |                                  |      |       |         |                        |             | 1  |
| Anoushiravani et al., 2016              | 5.3                     | 10.56                | 1762              | 4.4                              | 6.32 | 1787  | 11.10%  | 0.90 [0.33, 1.47]      | 2016        |  |
| Hung et al., 2019                       | 3.54                    | 0.6                  | 56                | 3.58                             | 0.63 | 697   | 16.00%  | -0.04 [-0.20, 0.12]    | 2019        | +  |
| Hartford et al., 2020                   | 2.7                     | 0.8                  | 13                | 2.7                              | 0.8  | 463   | 12.80%  | 0.00 [-0.44, 0.44]     | 2020        | +  |
| Subtotal (95%CI)                        |                         |                      | 1831              |                                  |      | 2947  | 39.90%  | 0.23 [-0.26, 0.71]     |             | •  |
| Heterogeneity: Tau <sup>2</sup> = 0.14; | Chi <sup>2</sup> = 9.56 | 5, df = 2 ( <i>P</i> | = 0.008);         | l <sup>2</sup> = 79%             |      |       |         |                        |             | •  |
| Test for overall effect: Z = 0.         | 92 ( <i>P</i> = 0.3     | 36)                  |                   |                                  |      |       |         |                        |             |  |
| 2.1.2 TKA                               |                         |                      |                   |                                  |      |       |         |                        |             |  |
| Anoushiravani et al., 2016              | 3.79                    | 4.25                 | 670               | 3.86                             | 5.74 | 645   | 11.40%  | -0.07 [-0.62, 0.48]    | 2016        |  |
| Manrrique et al., 2017                  | 3.7                     | 1                    | 27                | 3.4                              | 1.2  | 81    | 12.60%  | 0.30 [-0.16, 0.76]     | 2017        |  |
| Subtotal (95%CI)                        |                         |                      | 697               |                                  |      | 726   | 24.00%  | 0.15 [-0.21, 0.50]     |             |  |
| Heterogeneity: Tau <sup>2</sup> = 0.00; | Chi <sup>2</sup> = 1.03 | 3, df = 1 ( <i>P</i> | e = 0.31); /      | <sup>2</sup> = 3%                |      |       |         |                        |             | <b>•</b>                                       |
| Test for overall effect: Z = 0.         | .80 ( <i>P</i> = 0.4    | 12)                  |                   |                                  |      |       |         |                        |             |  |
| 2.2.3 THA and TKA                       |                         |                      |                   |                                  |      |       |         |                        |             |  |
| Shohat et al., 2018                     | 3                       | 2                    | 96                | 2.4                              | 1    | 3266  | 13.40%  | 0.60 [0.20, 1.00]      | 2018        |  |
| Sloan et al., 2019                      | 4.18                    | 9                    | 1846              | 3.14                             | 3.4  | 51130 | 13.20%  | 1.04 [0.63, 1.45]      | 2019        | -  |
| Katakam et al., 2020                    | 3.2                     | 3.3                  | 85                | 2.7                              | 1.4  | 821   | 9.40%   | 0.50 [-0.21, 1.21]     | 2020        | -  |
| Subtotal (95%CI)                        |                         |                      | 2027              |                                  |      | 55217 | 36.00%  | 0.76 [0.43, 1.09]      |             |  |
| Heterogeneity: Tau <sup>2</sup> = 0.03; | Chi² = 2.90             | ), df = 2 ( <i>P</i> | = 0.23); /2       | = 31%                            |      |       |         |                        |             | •  |
| Test for overall effect: Z = 4.         | 48 (P < 0.0             | 00001)               |                   |                                  |      |       |         |                        |             |  |
| Total (95%CI)                           |                         |                      | 4555              |                                  |      | 58890 | 100.00% | 0.39 [0.06, 0.72]      |             |  |
| Heterogeneity: Tau <sup>2</sup> = 0.17; | Chi <sup>2</sup> = 36.3 | 36, df = 7 (         | P < 0.000         | 01); <i>l</i> <sup>2</sup> = 81  | .%   |       |         |                        |             | •  |
| Test for overall effect: Z = 2.         | 31 (P = 0.0             | )2)                  |                   |                                  |      |       |         |                        |             |  |
| Test for subgroup difference            | es; Chi² = 6            | .88, df = 2          | ( <i>P</i> = 0.03 | ), <i>I</i> <sup>2</sup> = 70.99 | %    |       |         |                        |             | 4 -2 0 2 4<br>NW UW                            |
|   |                         |                      |                   |                                  |      |       |         | <b>DOI:</b> 10.12998/v | vjcc.v10.i3 | 80.10967 <b>Copyright</b> ©The Author(s) 2022. |

Figure 3 Length of hospital stay. CI: Confidence intervals; l': Heterogeneity; IV: Inverse variance; NW: Normal weight; SD: Standard deviation; THA: Total hip arthroplasty; TKA: Total knee arthroplasty; UW: Underweight.



**Figure 4 30–90-day Readmission rate.** CI: Confidence intervals; *I*<sup>2</sup>: Heterogeneity; M-H: Mantel-Haenszel; NW: Normal weight; THA: Total hip arthroplasty; TKA: Total knee arthroplasty; UW: Underweight.

Knee and hip osteoarthritis (OA) involves degeneration of articular cartilage, and bone hyperplasia of joint disease, is a common chronic disabling disease, causing physiological and psychological pain in patients[38]. OA is a common disease among the elderly, and elderly patients suffering from OA opt for arthroplasty for improved quality of life and morbidity-free life[39,40]. Modern-day arthroplasty includes the replacement of joints with a compatible metal prosthesis to restore function. TKA involves replacing the articular surfaces (femoral condyles and tibial plateau) of the knee joint with smooth metal and highly cross-linked polyethylene plastic[41,42]. THA involves the replacement of the acetabulum or

Ma YP et al. Underweight and total joint arthroplasty



DOI: 10.12998/wjcc.v10.i30.10967 Copyright ©The Author(s) 2022.

Figure 5 Re-operation rate. CI: Confidence intervals; P: Heterogeneity; M-H: Mantel-Haenszel; NW: Normal weight; THA: Total hip arthroplasty; TKA: Total knee arthroplasty; UW: Underweight.



Figure 6 Mortality. CI: Confidence intervals; P: Heterogeneity; M-H: Mantel-Haenszel; NW: Normal weight; THA: Total hip arthroplasty; TKA: Total knee

arthroplasty; UW: Underweight.

hip socket, and the head of the femur is removed and replaced with a metal replica[43]. TJA involves both THA and TKA carried out simultaneously to manage OA complications. The prognosis after undergoing both procedures is good and is considered to improve quality of life by reducing pain and increasing function[44].

BMI is considered one of the key predictive tools for assessing outcomes after TKA or THA. An extreme BMI level is believed to worsen the prognosis and is associated with increased complications after TKA or THA. Many systematic reviews have assessed the effect of BMI on these procedures. According to a recent systematic review [45], BMI higher than normal can affect the intra-operative risk of TKA and post-operative recovery, and increase the risk of complications. Another review [46] concluded that increased BMI was associated with an increased risk of peri-prosthetic joint infection (PJI) after primary THA or TKA. Following THA, patients were more likely to suffer from PJI than TKA





Figure 7 Post-operative infection. CI: Confidence intervals; P: Heterogeneity; M-H: Mantel-Haenszel; NW: Normal weight; THA: Total hip arthroplasty; TKA: Total knee arthroplasty; UW: Underweight.

|                                       |  |                                  |        | Hazard ratio              |                  | Hazard ratio                 |               |
|---------------------------------------|--|----------------------------------|--------|---------------------------|------------------|------------------------------|---------------|
| Study or subgroup                     | log [Hazard Ratio]                               | SE                               | Weight | IV, random 95%CI          |                  | IV, random 95%CI             |               |
| Hartford et al., 2020                 | 0.5188   | 0.6953                           | 33.70% | 1.68 [0.43 <i>,</i> 6.56] |                  |                              |               |
| Husted et al., 2016                   | -0.755   | 0.741                            | 30.70% | 0.47 [0.11, 2.01]         |                  |                              |               |
| Shaparin et al., 2016                 | 0.8329   | 0.6689                           | 35.60% | 2.30 [0.62, 8.53]         |                  | +                            |               |
| Total (95%CI)                         |  |                                  | 100%   | 1.27 [0.50, 3.22]         |                  | +                            |               |
| Heterogeneity: Tau <sup>2</sup> = 0.1 | .8; Chi <sup>2</sup> = 2.75, df = 2 ( <i>P</i> = | = 0.25); <i>I</i> <sup>2</sup> = | = 27%  |                           | 0.001            | 0.1 1 10                     | 1000          |
| Test for overall effect: Z =          | : 0.51 ( <i>P</i> = 0.61)                        |                                  |        |                           | F                | avours [NW] Favours [U       | W]            |
|                                       |  |                                  |        | <b>DOI:</b> 10.12998/w    | ricc.v10.i30.109 | 967 <b>Copyright</b> ©The Au | thor(s) 2022. |

Figure 8 Total complications. CI: Confidence intervals; P: Heterogeneity; IV: Inverse variance; NW: Normal weight; SE: Standard error; UW: Underweight.

patients. All the systematic reviews and meta-analyses conducted have focused on the effect of obesity or patients with high BMI on various outcomes after undergoing THA or TKA. However, some studies have shown that even low BMI or UW patients have shown both peri-operative morbidity and poor post-operative recovery with complications. A study [47] that evaluated the readmission rate and postoperative infection in UW patients undergoing THA, demonstrated that patients with BMI < 18.5 kg/m<sup>2</sup> were more likely to be associated with post-discharge infections and thereby increased readmission rates.

Most of the included studies classified underweight patients with a BMI < 18.5 kg/m<sup>2</sup>; however, a few studies such as those by Katakam et al[18] 2021 and Anoushiravani et al[30] 2016, used an up-bound cut-off of  $< 20 \text{ kg/m}^2$  and  $< 19.5 \text{ kg/m}^2$  to justify the fact that the present World Health Organization classification of BMI was set based on the findings in a young population and the included patients were elderly with a mean age of over 60 years.

The peri-operative outcomes assessed after undergoing arthroplasty include the operation duration and length of hospital stay. Our meta-analysis showed no significant difference in operation duration between UW and NW patients; however, the length of hospital stay after THA or TKA was found to be significantly higher for UW patients compared to NW patients with MD of 0.39 d 95% CI: [0.06, 0.72], P = 0.02. Poor nutritional status among UW patients leads to musculoskeletal degeneration characterized by



#### Ma YP et al. Underweight and total joint arthroplasty

|  | uw                           |                                | NW                   |              |                | Odds ratio                              |                 | Odds ratio                                 |
|--|------------------------------|--------------------------------|----------------------|--------------|----------------|---|-----------------|--|
| Study or subgroup  | Events                       | Total                          | Events               | Total        | Weight         | M-H, random, 95%Cl                      | Year            | M-H, random, 95%Cl                         |
| Anoushiravani et al., 2016   | 10                           | 1762                           | 10                   | 1787         | 4.90%          | 1.01 [0.42, 2.44]                       | 2016            |  |
| Dowsey et al., 2018  | 87                           | 492                            | 1233                 | 13226        | 9.50%          | 2.09 [1.65, 2.65]                       | 2018            | -  |
| Mouchti et al., 2018   | 185                          | 3588                           | 3963                 | 86336        | 9.90%          | 1.13 [0.97, 1.31]                       | 2018            | -  |
| Woo et al., 2019   | 49                           | 332                            | 48                   | 750          | 8.20%          | 2.53 [1.66, 3.86]                       | 2019            |  |
| Suptotal (95%CI)<br>Total events   | 221                          | 6174                           | 5254                 | 102099       | 32.40%         | 1.63 [1.03, 2.59]                       |                 | ◆  |
| Heterogeneity: Tau <sup>2</sup> = 0.18; Chi <sup>2</sup> =   | = 26.69, df = 3              | (P < 0.00001);                 | 1 <sup>2</sup> = 89% |              |                |   |                 |  |
| Test for overall effect: Z = 2.07 (P   | 9 = 0.04)                    |                                |                      |              |                |   |                 |  |
| 1.3.2 Infection  |                              |                                |                      |              |                |   |                 |  |
| Anoushiravani et al., 2016   | 5                            | 1762                           | 22                   | 1787         | 4.40%          | 0.23 [0.09, 0.60]                       | 2016            |  |
| Mouchti et al., 2018   | 9                            | 3588                           | 155                  | 86336        | 6.20%          | 1.40 [0.71, 2.74]                       | 2018            |  |
| Zusmanovich et al., 2018   | 1                            | 301                            | 2                    | 539          | 1.10%          | 0.90 [0.08, 9.91]                       | 2018            |  |
| Hung et al., 2019<br>Subtotal (95%CI)  | 0                            | 56                             | 2                    | 697<br>89359 | 0.70%          | 2.46 [0.12, 51.90]                      | 2019            |  |
| Total events   | 15                           | 3/0/                           | 181                  | 89339        | 12.50%         | 0.76 [0.21, 2.87]                       |                 | -  |
| Heterogeneity: Tau <sup>2</sup> = 0.99; Chi <sup>2</sup> =   | = 9.97, df = 3 (             | $P = 0.02$ ; $I^2 = 7$         | 0%                   |              |                |   |                 |  |
| Test for overall effect: Z = 0.43 (P   | 9 = 0.66)                    |                                |                      |              |                |   |                 |  |
| 1.3.3 DVT  |                              |                                |                      |              |                |   |                 |  |
| Zhang et al., 2012   | 0                            | 62                             | 2                    | 413          | 0.70%          | 1.32 [0.06, 27.75]                      | 2012            |  |
| Anousniravani et al., 2016<br>Zusmanovich et al., 2018   | 21                           | 201                            | 10                   | 520          | 5.70%          | 2.14 [1.01, 4.56]                       | 2016            | _ <b>_</b> _                               |
| Hartford et al., 2018  | 0                            | 13                             | 3                    | 463          | 0.70%          | 4.87 [0.24, 99.08]                      | 2010            |  |
| Subtotal (95%CI)   | -                            | 2138                           | -                    | 3202         | 7.80%          | 2.28 [1.14, 4.57]                       |                 |  |
| Total events   | 22                           |                                | 15                   |              |                | -                                       |                 | ◆  |
| Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> =   | = 0.67, df = 3 (             | $P = 0.88$ ; $I^2 = 0$         | %                    |              |                |   |                 |  |
| Test for overall effect: Z = 2.32 (P   | ' = 0.02)                    |                                |                      |              |                |   |                 |  |
| 1.3.4 PE   |                              | <i>co</i>                      |                      | ***          | 4 200          | 2 24 (0 22 24 25)                       | 2010            |  |
| ∠nang et al., 2012<br>Anoushiravani et al., 2016   | 1<br>9                       | 62<br>1762                     | 3<br>10              | 413<br>1787  | 1.20%<br>4.80% | 2.24 [U.23, 21.88]<br>0.91 [0.37. 2.25] | 2012<br>2016    | <u> </u>                                   |
| Husted et al., 2016  | 0                            | 77                             | 2                    | 2396         | 0.70%          | 6.18 [0.29, 129.80]                     | 2016            | _ <del>_</del>                             |
| Zusmanovich et al., 2018   | 1                            | 301                            | 1                    | 539          | 0.90%          | 1.79 [0.11, 28.77]                      | 2018            |  |
| Subtotal (95%CI)   |                              | 2202                           |                      | 5135         | 7.60%          | 1.21 [0.56, 2.63]                       |                 |  |
| Total events   | 11                           |                                | 16                   |              |                |   |                 | ←  |
| Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> =<br>Test for overall effect; Z = 0.48 (P | = 1.87, df = 3 (i<br>= 0.63) | $P = 0.60$ ; $I^2 = 0$         | %                    |              |                |   |                 |  |
|  | ,                            |                                |                      |              |                |   |                 |  |
| 1.3.5 Genitourinary<br>Anoushiravani et al., 2016  | 10                           | 1762                           | 20                   | 1787         | 5.60%          | 0.50 [0.24, 1.08]                       | 2016            |  |
| Zusmanovich et al., 2018   | 4                            | 301                            | 4                    | 539          | 2.70%          | 1.80 [0.45, 7.25]                       | 2018            |  |
| Subtotal (95%CI)   |                              | 2063                           |                      | 2326         | 8.40%          | 0.83 [0.25, 2.80]                       |                 |  |
| Total events   | 14                           |                                | 24                   |              |                |   |                 |  |
| Heterogeneity: Tau <sup>2</sup> = 0.48; Chi <sup>2</sup> =   | = 2.47, df = 1 (             | P = 0.12); I <sup>2</sup> = 6  | 0%                   |              |                |   |                 |  |
| Test for overall effect: Z = 0.30 (P   | = 0.76)                      |                                |                      |              |                |   |                 |  |
| 1.3. 6 Cardiac/infarction  |                              |                                |                      |              |                |   |                 |  |
| Anoushiravani et al., 2016   | 34                           | 1762                           | 9                    | 1/8/         | 5.80%          | 3.89 [1.86, 8.13]                       | 2016            |  |
| Zusmanovich et al., 2016   | 1                            | 301                            | 1                    | 2390         | 0.90%          | 1.79 [0.11, 28,77]                      | 2018            |  |
| Subtotal (95%CI)   | *                            | 2140                           | 1                    | 4722         | 7.30%          | 3.88 [1.93, 7.77]                       | 2010            |  |
| Total events   | 35                           |                                | 11                   |              |                |   |                 | •  |
| Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> =   | = 0.66, df = 2 (i            | $P = 0.72$ ; $I^2 = 0$         | %                    |              |                |   |                 |  |
| Test for overall effect: Z = 3.82 (P   | = 0.0001)                    |                                |                      |              |                |   |                 |  |
| 1.3. 7 Dislocation/subluxation   |                              |                                | -                    |              |                |   |                 |  |
| znang et al., 2012<br>Husted et al. 2016   | 4                            | 62<br>77                       | 3                    | 413          | 2.40%          | 9.43 [2.06, 43.18]                      | 2012            |  |
| Mouchti et al., 2016   | 8                            | 2599                           | 200                  | 2390         | 6.00%          | 2.06 [0.12, 30.31]                      | 2018            |  |
| Hung et al., 2019  | 0                            | 56                             | 3                    | 697          | 0.80%          | 1.76 [0.09, 34.42]                      | 2019            |  |
| Hartford et al., 2020  | 0                            | 13                             | 4                    | 463          | 0.80%          | 3.78 [0.19, 73.82]                      | 2020            |  |
| Subtotal (95%CI)   |                              | 3796                           |                      | 90305        | 10.80%         | 2.21 [0.55, 8.93]                       |                 |  |
| Total events<br>Heterogeneity: Tou <sup>2</sup> = 1.41; CL <sup>2</sup>                            | 12<br>= 10.81 df - 4         | (P = 0.021.12 -                | 307<br>63%           |              |                |   |                 | -  |
| Test for overall effect: Z = 1.11 (P   | = 0.27)                      | 0.03]; F =                     |                      |              |                |   |                 |  |
| 1.3. 8 Fracture  |                              |                                |                      |              |                |   |                 |  |
| Husted et al., 2016  | 0                            | 77                             | 6                    | 2396         | 0.80%          | 2.37 [0.13, 42.49]                      | 2016            |  |
| Mouchti et al., 2018   | 2                            | 3588                           | 40                   | 86336        | 2.70%          | 1.20 [0.29, 4.98]                       | 2018            |  |
| Hung et al., 2019  | 0                            | 56                             | 6                    | 697          | 0.80%          | 0.94 [0.05, 16.93]                      | 2019            |  |
| Hartford et al., 2020  | 1                            | 13                             | 26                   | 463          | 1.40%          | 1.40 [0.18, 11.19]                      | 2020            |  |
| Subtotal (95%CI)   | 2                            | 3734                           | 70                   | 89892        | 5.70%          | 1.32 [0.48, 3.64]                       |                 |  |
| Heterogeneity: Tau2 - 0.00: Chi2 -   | 3<br>= 0.23 df = 2 /         | $P = 0.971 \cdot l^2 - 0.0000$ | 78<br>%              |              |                |   |                 |  |
| Test for overall effect: Z = 0.53 (P   | = 0.60)                      | , - 0.97]; 1* = 0              |                      |              |                |   |                 |  |
| 1.3.9 Prosthetic malfunction /fra  | icture                       |                                |                      |              |                |   |                 |  |
| Husted et al., 2016  | 0                            | 77                             | 4                    | 2396         | 0.80%          | 3.43 [0.18, 64.27]                      | 2016            |  |
| Mouchti et al., 2018   | 11                           | 3588                           | 270                  | 86336        | 6.80%          | 0.98 [0.54, 1.79]                       | 2018            |  |
| Subtotal (95%CI)   |                              | 3665                           |                      | 88732        | 7.50%          | 1.03 [0.57, 1.86]                       |                 |  |
| Total events   | 11                           |                                | 274                  |              |                |   |                 | ◆  |
| Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> =<br>Test for overall effect: Z = 0.10 (P | = 0.68, df = 1 (i<br>= 0.92) | P = 0.41); l <sup>2</sup> = 0  | %                    |              |                |   |                 |  |
|  | -,                           |                                |                      |              |                |   |                 |  |
| Total (95% CI)<br>Total events   | 454                          | 31619                          | 6160                 | 475772       | 100.00%        | 1.44 [1.10, 1.88]                       |                 |  |
| Heterogeneity: $Tau^2 = 0.19$ ; $Chi^2 =$  | = 73.74, df = 3:             | 1 ( <i>P</i> < 0.0001);        | l <sup>2</sup> = 58% |              |                |   |                 |  |
| rescron overall effect: z = z.63 (P  | - 0.008)                     |                                |                      |              |                |   |                 |  |
| Test for subgroup differences; Ch  | i <sup>2</sup> = 12.65, df = | = 8 (P = 0.12), I <sup>2</sup> | = 36.7%              |              |                |   |                 | 0.005 0.1 1 10 200<br>NW UW                |
|  |                              |                                |                      |              |                | DOI:                                    | 10.12998/wjcc.v | v10.i30.10967 Copyright ©The Author(s) 202 |
|  |                              |                                |                      |              |                |   | -,,             |  |

Figure 9 Post-operative complications in patients undergoing total hip arthroplasty. CI: Confidence intervals; DVT: Deep vein thrombosis; P:

Baisbideng® WJCC | https://www.wjgnet.com

Heterogeneity; IV: Inverse variance; NW: Normal weight; PE: Pulmonary embolism; UW: Underweight.



Figure 10 Post-operative complications in patients undergoing total knee arthroplasty. CI: Confidence intervals; DVT: Deep vein thrombosis; P: Heterogeneity; IV: Inverse variance; NW: Normal weight; PE: Pulmonary embolism; UW: Underweight.

> less muscle mass, less soft tissue, and a greater probability of osteoporosis. A study in 2016[30] showed a higher proportion of UW patients with a length of hospital stay of more than 4 d compared to normal and obese patients. However, the mean difference of 0.39 d (= 9.4 h) for the length of hospital stay between UW and NW patients undergoing THA or TKA, though statistically significant, was not clinically significant. This negligible difference may be due to delay in discharge related to a systemlevel reason or inadequate staff availability.

> Our systematic review did not find any significant differences in readmission and re-operation rates for both UW and NW patients undergoing THA or TKA or TJA. Although not significant, the 30-90 readmission rate was more likely to be observed in UW patients, compared to NW patients. This result cannot be regarded as sufficient certainty as the readmission rate is positively affected by various independent risk factors such as age, male sex, black race, presence of pre-operative co-morbidities, and increased operation time following TKA[48].

> Our meta-analysis showed a significant association with post-operative mortality in UW patients OR: 2.20 95% CI: [1.43, 3.37]. UW patients can be malnourished, and often present with poor nutritional reserve. This may lead to a less pronounced immunological response. This may be a reasonable explanation for the higher incidence of post-operative mortality. The compromised immune response in these patients could trigger numerous debilitating diseases, leading to death. Additionally, patients undergoing both THA and TKA together showed an increased incidence of mortality with UW patients OR: 4.18 95%CI: [2.88, 6.07]. This could be explained by the fact that TJA (THA and TKA) is a more complicated surgery, with a higher incidence of complications than THA or TKA alone. A registry study [33] found U-shaped risk associations between BMI and perioperative cardiovascular events and mortality, which were highest in the UW group undergoing THA and TKA, suggesting that this was a subpopulation at risk.

> Several authors have evaluated complications in UW patients; however, some of the reported data is controversial. Many authors suggest that UW patients have a higher complication rate than their NW or even obese counterparts. Our meta-analysis of included studies regarding post-operative complications showed a significantly higher incidence of DVT and cardiac infarction among the post-operative complications observed in UW patients undergoing THA alone. Three studies[11,24,31] showed that UW patients undergoing THA or TKA had increased risks for infection, cardiac complications, and venous thrombo-emboli. The reason for this is not entirely clear; however, in their studies, it appears



that the UW group tended to have lower preoperative hematocrit and albumin which are markers of malnutrition and predispose patients to medical complications. Nowadays, autologous platelet concentrates[49-51] have been proved to be beneficial in the management of bone-related disorders[52-55]. They have also been used as an adjunct to arthroplasty [56,57]. Many studies have opted for this as an alternative to arthroplasty [58,59]. This can be used as an alternative to arthroplasty in less severe cases to improve the quality of life in UW patients.

Our systematic review and meta-analysis are the first to assess the impact of UW on peri-operative and post-operative outcomes of THA or TKA. However, our review also has certain limitations. Confounding factors such as age, presence of comorbidities including anemia, diabetes, hypertension, patients using anticoagulants, and preoperative use of any walking aids, were not taken into consideration to assess the peri-operative outcomes and readmission or reoperation rates. Moreover, no subgroup analysis could be performed based on follow-up time, especially on 30-d and 90-d readmission rates. The exclusion of articles other than the English language could also be a possible limitation as good evidence could have been missed.

#### CONCLUSION

UW patients undergoing THA or TKA had a higher incidence of post-operative complications and readmission rates. Moreover, UW patients undergoing TJA were associated with an increased incidence of mortality in the 31-365-d time frame. Also, a higher incidence of DVT and cardiac infarction was evident among all the post-operative complications in UW patients undergoing THA. No difference in post-operative complications was found in UW patients undergoing TKA. Hence, careful clinical judgment is needed by clinicians before UW patients undergo THA or TKA.

#### ARTICLE HIGHLIGHTS

#### Research background

The effect of body mass index (BMI) on the outcomes and complications associated with total hip arthroplasty (THA) and total knee arthroplasty (TKA) is less studied and is believed to be a determining factor.

#### Research motivation

Systematic reviews on this issue have primarily focused on obesity compared to normal weight (NW). None of these reviews attempted to assess the effect of low BMI or underweight (UW) compared to NW in patients undergoing THA or TKA.

#### Research objectives

The objective of this review was to compare specific operative outcomes such as operation duration, length of hospital stay, and post-operative complications including mortality, infections, deep vein thrombosis, etc. along with rehospitalization and reoperation rates between UW and NW patients undergoing THA or TKA or both.

#### Research methods

An electronic search was performed in PubMed, Scopus, Excerpta Medica database (EMBASE), Web of Science (WoS), and Cochrane Central Register of Controlled Trials (CENTRAL) along with a manual search. The quality of the studies was assessed using the Newcastle-Ottawa scale for cohort studies. The data were subjected to both qualitative and quantitative analysis.

#### Research results

Thirteen retrospective and five prospective cohort studies were included. The quality of included studies was assessed to be good to fair. The length of hospital stay after TKA or THA was found to be significantly higher for UW patients when compared to NW patients. Mean difference: 0.39 95% CI: [0.06, 0.72], P = 0.02 (in days). Studies presenting both THA and TKA together as total joint arthroplasty showed an increased incidence of mortality in patients who underwent THA or TKA alone with an odds ratio: 4.18 95%CI: [2.88, 6.07]. A higher incidence of post-operative complications was also observed in UW patients undergoing THA.

#### **Research conclusions**

UW patients undergoing THA or TKA had a higher incidence of post-operative complications and were associated with a higher readmission rate. Moreover, UW patients were associated with an increased incidence of mortality in the studies that reported THA and TKA together.



#### Research perspectives

Careful clinical judgment is needed by clinicians before UW patients undergo THA or TKA to attain better outcomes.

#### FOOTNOTES

Author contributions: Ma YP conceived and designed the study; Ma YP and Shen Q were involved in the literature search and data collection; Ma YP analyzed the data; Ma YP and Shen Q wrote the paper; Ma YP edited the manuscript; all authors read and approved the final manuscript.

Conflict-of-interest statement: All the authors declare no competing interest.

PRISMA 2009 Checklist statement: The authors have read the PRISMA checklist and the manuscript was prepared and revised according to the PRISMA checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

#### Country/Territory of origin: China

**ORCID number:** Yun-Ping Ma 0000-0002-0306-921X; Qiu Shen 0000-0001-7895-0688.

S-Editor: Liu JH L-Editor: Webster JR P-Editor: Liu JH

#### REFERENCES

- Sun K, Li H. Body mass index as a predictor of outcome in total knee replace: A systemic review and meta-analysis. Knee 1 2017; 24: 917-924 [PMID: 28666646 DOI: 10.1016/j.knee.2017.05.022]
- Nuttall FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today 2015; 50: 117-128 [PMID: 2 27340299 DOI: 10.1097/NT.000000000000092]
- Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc 3 Nurse Pract 2017; 29: S3-S14 [PMID: 29024553 DOI: 10.1002/2327-6924.12510]
- Wallace G, Judge A, Prieto-Alhambra D, de Vries F, Arden NK, Cooper C. The effect of body mass index on the risk of post-operative complications during the 6 months following total hip replacement or total knee replacement surgery. Osteoarthritis Cartilage 2014; 22: 918-927 [PMID: 24836211 DOI: 10.1016/j.joca.2014.04.013]
- 5 George J, Piuzzi NS, Ng M, Sodhi N, Khlopas AA, Mont MA. Association Between Body Mass Index and Thirty-Day Complications After Total Knee Arthroplasty. J Arthroplasty 2018; 33: 865-871 [PMID: 29107493 DOI: 10.1016/j.arth.2017.09.038
- Russo MW, Macdonell JR, Paulus MC, Keller JM, Zawadsky MW. Increased Complications in Obese Patients Undergoing Direct Anterior Total Hip Arthroplasty. J Arthroplasty 2015; 30: 1384-1387 [PMID: 25820116 DOI: 10.1016/j.arth.2015.03.002
- Boyce L, Prasad A, Barrett M, Dawson-Bowling S, Millington S, Hanna SA, Achan P. The outcomes of total knee arthroplasty in morbidly obese patients: a systematic review of the literature. Arch Orthop Trauma Surg 2019; 139: 553-560 [PMID: 30778723 DOI: 10.1007/s00402-019-03127-5]
- 8 Lim YZ, Wang Y, Cicuttini FM, Giles GG, Graves S, Wluka AE, Hussain SM. Obesity defined by body mass index and waist circumference and risk of total knee arthroplasty for osteoarthritis: A prospective cohort study. PLoS One 2021; 16: e0245002 [PMID: 33411773 DOI: 10.1371/journal.pone.0245002]
- Zusmanovich M, Kester B, Feng J, Schwarzkopf R. Postoperative complications in underweight patients undergoing total hip arthroplasty: A comparative analysis to normal weight patients. J Orthop 2018; 15: 345-348 [PMID: 29881150 DOI: 10.1016/j.jor.2018.02.016]
- 10 Manrique J, Chen AF, Gomez MM, Maltenfort MG, Hozack WJ. Surgical site infection and transfusion rates are higher in underweight total knee arthroplasty patients. Arthroplast Today 2017; 3: 57-60 [PMID: 28378008 DOI: 10.1016/j.artd.2016.03.005
- Molloy IB, Martin BI, Moschetti WE, Jevsevar DS. Effects of the Length of Stay on the Cost of Total Knee and Total Hip 11 Arthroplasty from 2002 to 2013. J Bone Joint Surg Am 2017; 99: 402-407 [PMID: 28244911 DOI: 10.2106/JBJS.16.00019]
- Foote J, Panchoo K, Blair P, Bannister G. Length of stay following primary total hip replacement. Ann R Coll Surg Engl 2009; 91: 500-504 [PMID: 19558767 DOI: 10.1308/003588409X432356]
- 13 Abdulla I, Mahdavi S, Khong H, Gill R, Powell J, Johnston KD, Sharma R. Does body mass index affect the rate of adverse outcomes in total hip and knee arthroplasty? Can J Surg 2020; 63: E142-E149 [PMID: 32216250 DOI: 10.1503/cjs.006719]



- 14 Elsiwy Y, Jovanovic I, Doma K, Hazratwala K, Letson H. Risk factors associated with cardiac complication after total joint arthroplasty of the hip and knee: a systematic review. J Orthop Surg Res 2019; 14: 15 [PMID: 30635012 DOI: 10.1186/s13018-018-1058-9
- 15 Pozzobon D, Ferreira PH, Blyth FM, Machado GC, Ferreira ML. Can obesity and physical activity predict outcomes of elective knee or hip surgery due to osteoarthritis? BMJ Open 2018; 8: e017689 [PMID: 29487072 DOI: 10.1136/bmjopen-2017-017689]
- Onggo JR, Onggo JD, de Steiger R, Hau R. Greater risks of complications, infections, and revisions in the obese versus 16 non-obese total hip arthroplasty population of 2,190,824 patients: a meta-analysis and systematic review. Osteoarthritis Cartilage 2020; 28: 31-44 [PMID: 31705995 DOI: 10.1016/j.joca.2019.10.005]
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. 17 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700 [PMID: 19622552 DOI: 10.1136/bmj.b2700]
- Katakam A, Melnic CM, Bragdon CR, Sauder N, Collins AK, Bedair HS. Low Body Mass Index Is a Predictor for Mortality and Increased Length of Stay Following Total Joint Arthroplasty. J Arthroplasty 2021; 36: 72-77 [PMID: 32807566 DOI: 10.1016/j.arth.2020.07.055]
- Kwon HM, Han CD, Yang IH, Lee WS, Kim CW, Park KK. Being Underweight Is Associated with Worse Surgical 19 Outcomes of Total Knee Arthroplasty Compared to Normal Body Mass Index in Elderly Patients. Orthop Res Rev 2020; 12: 53-60 [PMID: 32308506 DOI: 10.2147/ORR.S243444]
- Hartford JM, Graw BP, Frosch DL. Perioperative Complications Stratified by Body Mass Index for the Direct Anterior 20 Approach to Total Hip Arthroplasty. J Arthroplasty 2020; 35: 2652-2657 [PMID: 32389402 DOI: 10.1016/j.arth.2020.04.018
- 21 Woo SH, Cha DH, Park EC, Kim SJ. The association of under-weight and obesity with mortality after hip arthroplasty. Age Ageing 2019; 48: 94-100 [PMID: 30304489 DOI: 10.1093/ageing/afy161]
- 22 Sloan M, Sheth N, Lee GC. Is Obesity Associated With Increased Risk of Deep Vein Thrombosis or Pulmonary Embolism After Hip and Knee Arthroplasty? Clin Orthop Relat Res 2019; 477: 523-532 [PMID: 30624321 DOI: 10.1097/CORR.000000000000615
- 23 Sayed-Noor AS, Mukka S, Mohaddes M, Kärrholm J, Rolfson O. Body mass index is associated with risk of reoperation and revision after primary total hip arthroplasty: a study of the Swedish Hip Arthroplasty Register including 83,146 patients. Acta Orthop 2019; 90: 220-225 [PMID: 30931664 DOI: 10.1080/17453674.2019.1594015]
- 24 Hung CY, Chang CH, Lin YC, Lee SH, Chen SY, Hsieh PH. Predictors for Unfavorable Early Outcomes in Elective Total Hip Arthroplasty: Does Extreme Body Mass Index Matter? Biomed Res Int 2019; 2019: 4370382 [PMID: 31687390 DOI: 10.1155/2019/4370382]
- Shohat N, Fleischman A, Tarabichi M, Tan TL, Parvizi J. Weighing in on Body Mass Index and Infection After Total Joint 25 Arthroplasty: Is There Evidence for a Body Mass Index Threshold? Clin Orthop Relat Res 2018; 476: 1964-1969 [PMID: 30794240 DOI: 10.1007/s11999.000000000000141]
- 26 Mouchti S, Whitehouse MR, Sayers A, Hunt LP, MacGregor A, Blom AW. The Association of Body Mass Index with Risk of Long-Term Revision and 90-Day Mortality Following Primary Total Hip Replacement: Findings from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man. J Bone Joint Surg Am 2018; 100: 2140-2152 [PMID: 30562295 DOI: 10.2106/JBJS.18.00120]
- 27 Dowsey MM, Choong PFM, Paxton EW, Spelman T, Namba RS, Inacio MCS. Body Mass Index Is Associated With Allcause Mortality After THA and TKA. Clin Orthop Relat Res 2018; 476: 1139-1148 [PMID: 29775187 DOI: 10.1007/s11999.000000000000108]
- Shaparin N, Widyn J, Nair S, Kho I, Geller D, Delphin E. Does the obesity paradox apply to early postoperative 28 complications after hip surgery? J Clin Anesth 2016; 32: 84-91 [PMID: 27290953 DOI: 10.1016/j.jclinane.2015.12.037]
- 29 Husted H, Jørgensen CC, Gromov K, Kehlet H; Lundbeck Foundation Center for Fast-track Hip and Knee Replacement Collaborative Group. Does BMI influence hospital stay and morbidity after fast-track hip and knee arthroplasty? Acta Orthop 2016; 87: 466-472 [PMID: 27347785 DOI: 10.1080/17453674.2016.1203477]
- 30 Anoushiravani AA, Sayeed Z, Chambers MC, Gilbert TJ, Scaife SL, El-Othmani MM, Saleh KJ. Assessing In-Hospital Outcomes and Resource Utilization After Primary Total Joint Arthroplasty Among Underweight Patients. J Arthroplasty 2016; 31: 1407-1412 [PMID: 27133161 DOI: 10.1016/j.arth.2015.12.053]
- Zhao J, Li J, Zheng W, Liu D, Sun X, Xu W. Low body mass index and blood loss in primary total hip arthroplasty: results 31 from 236 consecutive ankylosing spondylitis patients. Biomed Res Int 2014; 2014: 742393 [PMID: 24959587 DOI: 10.1155/2014/742393]
- Thornqvist C, Gislason GH, Køber L, Jensen PF, Torp-Pedersen C, Andersson C. Body mass index and risk of 32 perioperative cardiovascular adverse events and mortality in 34,744 Danish patients undergoing hip or knee replacement. Acta Orthop 2014; 85: 456-462 [PMID: 24954493 DOI: 10.3109/17453674.2014.934184]
- 33 Zhang ZJ, Zhao XY, Kang Y, Zhang ZQ, Yang ZB, He AS, Fu M, Sheng PY, Liao WM. The influence of body mass index on life quality and clinical improvement after total hip arthroplasty. J Orthop Sci 2012; 17: 219-225 [PMID: 22323012 DOI: 10.1007/s00776-012-0197-9]
- Roth A, Anis HK, Emara AK, Klika AK, Barsoum WK, Bloomfield MR, Brooks PJ, Higuera CA, Kamath AF, Krebs VE, 34 Mesko NW, Murray TG, Muschler GF, Nickodem RJ, Patel PD, Schaffer JL, Stearns KL, Strnad G, Warren JA, Zajichek A, Mont MA, Molloy RM, Piuzzi NS; Cleveland Clinic OME Arthroplasty Group. The Potential Effects of Imposing a Body Mass Index Threshold on Patient-Reported Outcomes After Total Knee Arthroplasty. J Arthroplasty 2021; 36: S198-S208 [PMID: 32981774 DOI: 10.1016/j.arth.2020.08.060]
- 35 Murgatroyd SE, Frampton CM, Wright MS. The effect of body mass index on outcome in total hip arthroplasty: early analysis from the New Zealand Joint Registry. J Arthroplasty 2014; 29: 1884-1888 [PMID: 25042579 DOI: 10.1016/j.arth.2014.05.024]
- 36 Guan Z, Chen Y, Song Y. [Influence of body mass index and age on deep vein thrombosis after total hip and knee arthroplasty]. Zhongguo Xiufu Chongjian Waike Zazhi 2006; 20: 611-615



- 37 Heidari B. Knee osteoarthritis prevalence, risk factors, pathogenesis and features: Part I. Caspian J Intern Med 2011; 2: 205-212 [PMID: 24024017]
- 38 Hamel MB, Toth M, Legedza A, Rosen MP. Joint replacement surgery in elderly patients with severe osteoarthritis of the hip or knee: decision making, postoperative recovery, and clinical outcomes. Arch Intern Med 2008; 168: 1430-1440 [PMID: 18625924 DOI: 10.1001/archinte.168.13.1430]
- Katz JN, Arant KR, Loeser RF. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA 2021; 325: 39 568-578 [PMID: 33560326 DOI: 10.1001/jama.2020.22171]
- 40 Softness KA, Murray RS, Evans BG. Total knee arthroplasty and fractures of the tibial plateau. World J Orthop 2017; 8: 107-114 [PMID: 28251061 DOI: 10.5312/wjo.v8.i2.107]
- Feng JE, Novikov D, Anoushiravani AA, Schwarzkopf R. Total knee arthroplasty: improving outcomes with a 41 multidisciplinary approach. J Multidiscip Healthc 2018; 11: 63-73 [PMID: 29416347 DOI: 10.2147/JMDH.S140550]
- Varacallo M, Luo TD, Johanson NA. Total Hip Arthroplasty Techniques. In: StatPearls. Treasure Island (FL): StatPearls 42 Publishing, 2021 Available from: http://www.ncbi.nlm.nih.gov/books/NBK507864/
- 43 Bumpass DB, Nunley RM. Assessing the value of a total joint replacement. Curr Rev Musculoskelet Med 2012; 5: 274-282 [PMID: 23054621 DOI: 10.1007/s12178-012-9139-6]
- 44 Wang H, Qiong M, Ma B. Analysis of the influence of BMI on the outcome after total knee arthroplasty. IJS Glob Health 2021; 4: e55 [DOI: 10.1097/GH9.00000000000055]
- 45 Zhong J, Wang B, Chen Y, Li H, Lin N, Xu X, Lu H. Relationship between body mass index and the risk of periprosthetic joint infection after primary total hip arthroplasty and total knee arthroplasty. Ann Transl Med 2020; 8: 464 [PMID: 32395508 DOI: 10.21037/atm.2020.03.112]
- Alfonso DT, Howell RD, Caceres G, Kozlowski P, Di Cesare PE. Total hip arthroplasty in the underweight. J Arthroplasty 2008; 23: 956-959 [PMID: 18534502 DOI: 10.1016/j.arth.2007.09.008]
- 47 Lehtonen EJ, Hess MC, McGwin G Jr, Shah A, Godoy-Santos AL, Naranje S. RISK FACTORS FOR EARLY HOSPITAL READMISSION FOLLOWING TOTAL KNEE ARTHROPLASTY. Acta Ortop Bras 2018; 26: 309-313 [PMID: 30464711 DOI: 10.1590/1413-785220182605190790]
- 48 Panda S, Mishra L, Arbildo-Vega HI, Lapinska B, Lukomska-Szymanska M, Khijmatgar S, Parolia A, Bucchi C, Fabbro MD. Effectiveness of Autologous Platelet Concentrates in Management of Young Immature Necrotic Permanent Teeth-A Systematic Review and Meta-Analysis. Cells 2020; 9 [PMID: 33036462 DOI: 10.3390/cells9102241]
- Panda S, Satpathy A, Chandra Das A, Kumar M, Mishra L, Gupta S, Srivastava G, Lukomska-Szymanska M, Taschieri S, Del Fabbro M. Additive Effect of Platelet Rich Fibrin with Coronally Advanced Flap Procedure in Root Coverage of Miller's Class I and II Recession Defects-A PRISMA Compliant Systematic Review and Meta-Analysis. Materials (Basel) 2020; 13 [PMID: 32992613 DOI: 10.3390/ma13194314]
- 50 Panda S, Purkayastha A, Mohanty R, Nayak R, Satpathy A, DAS AC, Kumar M, Mohanty G, Panda S, Fabbro MD. Plasma rich in growth factors (PRGF) in non-surgical periodontal therapy: a randomized clinical trial. Braz Oral Res 2020; **34**: e034 [PMID: 32321052 DOI: 10.1590/1807-3107bor-2020.vol34.0034]
- 51 Panda S, Doraiswamy J, Malaiappan S, Varghese SS, Del Fabbro M. Additive effect of autologous platelet concentrates in treatment of intrabony defects: a systematic review and meta-analysis. J Investig Clin Dent 2016; 7: 13-26 [PMID: 25048153 DOI: 10.1111/jicd.121171
- Del Fabbro M, Lolato A, Panda S, Corbella S, Satpathy A, Das AC, Kumar M, Taschieri S. Methodological Quality 52 Assessment of Systematic Reviews on Autologous Platelet Concentrates for the Treatment of Periodontal Defects. J Evid Based Dent Pract 2017; 17: 239-255 [PMID: 28865820 DOI: 10.1016/j.jebdp.2017.04.006]
- 53 Del Fabbro M, Karanxha L, Panda S, Bucchi C, Nadathur Doraiswamy J, Sankari M, Ramamoorthi S, Varghese S, Taschieri S. Autologous platelet concentrates for treating periodontal infrabony defects. Cochrane Database Syst Rev 2018; 11: CD011423 [PMID: 30484284 DOI: 10.1002/14651858.CD011423.pub2]
- Panda S, Ramamoorthi S, Jayakumar ND, Sankari M, Varghese SS. Platelet rich fibrin and alloplast in the treatment of 54 intrabony defect. J Pharm Bioallied Sci 2014; 6: 127-131 [PMID: 24741282 DOI: 10.4103/0975-7406.129178]
- Safdar A, Shaaban H, Tibayan R, Miller R, Boairdo R, Guron G. The clinical efficacy of using autologous platelet rich 55 plasma in hip arthroplasty: A retrospective comparative study. J Nat Sci Biol Med 2015; 6: 49-55 [PMID: 25810634 DOI: 10.4103/0976-9668.149077]
- Guerreiro JP, Danieli MV, Queiroz AO, Deffune E, Ferreira RR. Platelet-rich plasma (PRP) applied during total knee 56 arthroplasty. Rev Bras Ortop 2015; 50: 186-194 [PMID: 26229915 DOI: 10.1016/j.rboe.2015.02.014]
- Prodromos C, Finkle S. Autologous Biologic Treatment with Fat, Bone Marrow Aspirate and Platelet Rich Plasma Is an Effective Alternative to Total Knee Arthroplasty for Patients with Moderate Knee Arthrosis. Medicines (Basel) 2020; 7 [PMID: 32630375 DOI: 10.3390/medicines7060037]
- Sánchez M, Jorquera C, Sánchez P, Beitia M, García-Cano B, Guadilla J, Delgado D. Platelet-rich plasma injections delay 58 the need for knee arthroplasty: a retrospective study and survival analysis. Int Orthop 2021; 45: 401-410 [PMID: 32621139 DOI: 10.1007/s00264-020-04669-91
- Pace TB, Foret JL, Palmer MJ, Tanner SL, Snider RG. Intraoperative platelet rich plasma usage in total knee arthroplasty: does it help? ISRN Orthop 2013; 2013: 740173 [PMID: 24971180 DOI: 10.1155/2013/740173]





# Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

